BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller S, Leishman E, Hu SS, Elghouche A, Daily L, Murataeva N, Bradshaw H, Straiker A. Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model. Invest Ophthalmol Vis Sci 2016;57:3287-96. [PMID: 27333182 DOI: 10.1167/iovs.16-19356] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Toguri J, Leishman E, Szczesniak A, Laprairie R, Oehler O, Straiker A, Kelly M, Bradshaw H. Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye. Prostaglandins & Other Lipid Mediators 2018;139:54-62. [DOI: 10.1016/j.prostaglandins.2018.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
2 Rapino C, Tortolani D, Scipioni L, Maccarrone M. Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases. Curr Neuropharmacol 2018;16:959-70. [PMID: 28738764 DOI: 10.2174/1570159X15666170724104305] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
3 Miller S, Daily L, Dharla V, Gertsch J, Malamas MS, Ojima I, Kaczocha M, Ogasawara D, Straiker A. Endocannabinoid metabolism and transport as targets to regulate intraocular pressure. Exp Eye Res 2020;201:108266. [PMID: 32979397 DOI: 10.1016/j.exer.2020.108266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Miller S, Daily L, Ploss M, Greig I, Ross R, Rayana NP, Dai J, Sugali CK, Mao W, Straiker A. Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms. Exp Eye Res 2020;200:108241. [PMID: 32941875 DOI: 10.1016/j.exer.2020.108241] [Reference Citation Analysis]
5 Miller S, Hu SS, Leishman E, Morgan D, Wager-Miller J, Mackie K, Bradshaw HB, Straiker A. A GPR119 Signaling System in the Murine Eye Regulates Intraocular Pressure in a Sex-Dependent Manner. Invest Ophthalmol Vis Sci 2017;58:2930-8. [PMID: 28593245 DOI: 10.1167/iovs.16-21330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
6 Miller S, Kulkarni S, Ciesielski A, Nikas SP, Mackie K, Makriyannis A, Straiker A. Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure. Pharmaceuticals (Basel) 2018;11:E50. [PMID: 29786643 DOI: 10.3390/ph11020050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
7 Lafreniere JD, Kelly MEM. Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options. Neuronal Signal 2018;2:NS20170144. [PMID: 32714590 DOI: 10.1042/NS20170144] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 Miller S, Daily L, Leishman E, Bradshaw H, Straiker A. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Invest Ophthalmol Vis Sci 2018;59:5904-11. [PMID: 30550613 DOI: 10.1167/iovs.18-24838] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
9 Jordan E, Nguyen GN, Piechot A, Kayser O. Cannabinoids as New Drug Candidates for the Treatment of Glaucoma. Planta Med 2022. [PMID: 35299275 DOI: 10.1055/a-1665-3100] [Reference Citation Analysis]
10 Thayer A, Murataeva N, Delcroix V, Wager-Miller J, Makarenkova HP, Straiker A. THC Regulates Tearing via Cannabinoid CB1 Receptors. Invest Ophthalmol Vis Sci 2020;61:48. [PMID: 32852544 DOI: 10.1167/iovs.61.10.48] [Reference Citation Analysis]
11 Abyadeh M, Gupta V, Paulo JA, Gupta V, Chitranshi N, Godinez A, Saks D, Hasan M, Amirkhani A, McKay M, Salekdeh GH, Haynes PA, Graham SL, Mirzaei M. A Proteomic View of Cellular and Molecular Effects of Cannabis. Biomolecules 2021;11:1411. [PMID: 34680044 DOI: 10.3390/biom11101411] [Reference Citation Analysis]
12 Argikar UA, Dumouchel JL, Dunne CE, Bushee AJ. Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes. Drug Metab Rev 2017;49:372-94. [PMID: 28438049 DOI: 10.1080/03602532.2017.1322609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
13 Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM. The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. J Ocul Pharmacol Ther 2017;33:582-90. [PMID: 28719234 DOI: 10.1089/jop.2017.0037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
14 Alapafuja SO, Malamas MS, Shukla V, Zvonok A, Miller S, Daily L, Rajarshi G, Miyabe CY, Chandrashekhar H, Wood J, Tyukhtenko S, Straiker A, Makriyannis A. Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment. Bioorg Med Chem 2019;27:55-64. [PMID: 30446439 DOI: 10.1016/j.bmc.2018.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
15 Kokona D, Spyridakos D, Tzatzarakis M, Papadogkonaki S, Filidou E, Arvanitidis KI, Kolios G, Lamani M, Makriyannis A, Malamas MS, Thermos K. The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology 2021;185:108450. [PMID: 33450278 DOI: 10.1016/j.neuropharm.2021.108450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]